- INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION
-
Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
- -
-
Paragraph 1831-1832; 1877-1888
(2020/03/01)
-
- Preparation method and application of novel spiro compound
-
The invention discloses a preparation method and application of a novel spiro compound and belongs to the technical field of pesticide synthesis. Compared with the prior art, the preparation method and application have the advantage that the novel spiro c
- -
-
Paragraph 0026; 0027
(2018/05/01)
-
- Triazole methyl ester linked spiro compound with antibacterial activity, and preparation method and application thereof
-
The invention discloses a triazole methyl ester linked spiro compound with antibacterial activity, and a preparation method and application thereof, and belongs to the technical field of medicine synthesis. The key point of the technical scheme is as follows: the triazole methyl ester linked spiro compound with antibacterial activity has the following structure: (the formula is shown in the description). The invention also discloses a preparation method of the triazole methyl ester linked spiro compound with antibacterial activity. The reaction process is simple and practical in operation, theraw materials are cheap and easily available, the reaction efficiency is high, the repeatability is high, and a remarkable inhibition effect on escherichia coli is achieved.
- -
-
Paragraph 0027; 0028
(2018/05/16)
-
- HETEROBICYCLIC COMPOUNDS
-
Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.
- -
-
Paragraph 0573
(2013/09/12)
-
- ACYLGUANIDINE DERIVATIVE
-
An object of the present invention is to provide an excellent agent for treating or preventing dementia, schizophrenia based on a serotonin 5-HT5A receptor modulating action. It was confirmed that acylguanidine derivatives, which has the charac
- -
-
Page/Page column 10
(2012/01/03)
-
- NOVEL NAPHTHYRIDINE DERIVATIVE MONOHYDRATE AND METHOD FOR PRODUCING THE SAME
-
Disclosed is 1-(2-(4-((2,3-dihydro(1,4)dioxino(2,3-c)pyridin-7-ylmethyl)amino)piperidin-1-yl)ethyl)-7-fluoro-1,5-naphthyridin-2(1H)-one monohydrate, which has strong antibacterial activity. The compound is highly safe and useful as an original drug for ph
- -
-
Page/Page column 15
(2010/09/05)
-
- NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF
-
Disclosed is a compound represented by the general formula: [wherein R1 represents an aryl or heterocyclic group which may be substituted or the like; X1 represents a C2-C4 alkylene group or the like; X2, X3 and X5 independently represent NH, a bond or the like; X4 represents a lower alkylene group, a bond or the like; Y1 represents a bivalent alicyclic hydrocarbon residue which may be substituted or a bivalent alicyclic amine residue which may be substituted; and Z1, Z2, Z3, Z4, Z5 and Z6 independently represent a nitrogen atom, a group represented by the formula: CH, or the like, provided that at least one of Z3, Z4, Z5 and Z6 represents a nitrogen atom] or a salt thereof, which is useful as an antibacterial agent.
- -
-
Page/Page column 94
(2009/03/07)
-